Healthlead PCL (BKK:HL) Research & Development: ฿0 Mil (TTM As of Mar. 2026)


BKK:HL Healthlead PCL BKK:HL
76 GF Score
Price ฿5.50
GF Value ฿10.82
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Healthlead PCL Research & Development?

Healthlead PCL BKK:HL -1.79% 76 Research & Development is ฿0 Mil as of Mar. 2026. GuruFocus rates BKK:HL with a GF Score™ of 76/100 and a GF Value™ of ฿10.82 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Healthlead PCL's Research & Development for the three months ended in Mar. 2026 was ฿0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ฿0 Mil.

Healthlead PCL  (BKK:HL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Healthlead PCL Research & Development Related Terms

Healthlead PCL Research & Development Historical Data

* Premium members only.

The historical data trend for Healthlead PCL's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healthlead PCL Research & Development Chart

Healthlead PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Healthlead PCL Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BKK:HL
76GF Score
Healthlead PCL BKK:HL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healthlead PCL Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ฿0 Mil mean?
Healthlead PCL (BKK:HL) has a Research & Development of ฿0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Healthlead PCL and its competitors.
Is Healthlead PCL's Research & Development too high?
Healthlead PCL's current Research & Development is ฿0 Mil. Overall, Healthlead PCL has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's Research & Development compare to competitors?
Healthlead PCL's Research & Development of ฿0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Healthlead PCL and its competitors. Healthlead PCL's current Research & Development is ฿0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿10.82, compared to a current price of ฿5.50 — trading 49.2% below its estimated fair value. The current Research & Development is ฿0 Mil. Healthlead PCL's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current Research & Development is ฿0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healthlead PCL (BKK:HL) Overvalued in 2026?

Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued. The current stock price of ฿5.50 is trading 49.2% below its estimated GF Value™ of ฿10.82. GuruFocus considers Healthlead PCL to be Significantly Undervalued.

Key valuation signals for BKK:HL:

  • Research & Development: ฿0 Mil
  • GF Value™: ฿10.82 vs. price of ฿5.50 (49.2% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healthlead PCL Business Description

Address 99/4 Moo 10, Bang Muang Sub-District, Bang-Yai District, Nonthaburi, THA, 11140
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
76GF Score

Get the complete analysis for BKK:HL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿5.50
Price
฿10.82
GF Value